Previous close | 14.50 |
Open | 14.50 |
Bid | 8.90 |
Ask | 12.90 |
Strike | 27.00 |
Expiry date | 2024-09-20 |
Day's range | 14.50 - 14.50 |
Contract range | N/A |
Volume | |
Open interest | 6 |
PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients. At Month 12, PTC518 treatment resulted in dose-dependent lowering of mutant huntingtin (mHTT) protein in the blood and cerebrospinal fluid (CSF) in the interim cohort of patients. In addition, favorable trends were demonstrated on several relevant HD clinical assessments including Total Motor Score (TMS) and Composite Unified Huntington's Disease Rat
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference:
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA.